Understanding the Role of Early Diagnosis and Treatment in PAH in the Context of Racial and Ethnic Disparities: Nurse Practitioners on the Frontlines of Care




This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ANCC and AANP credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.


This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.


In order for patients with pulmonary arterial hypertension (PAH) to have the best outcomes, early diagnosis and treatment are necessary to avoid irreversible pathologic changes. Unfortunately, about 20% of patients with PAH exhibit symptoms for over 2 years before a diagnosis is made. In addition, studies also show racial discrepancies between outcomes specific to PAH in addition to more general findings concerning race, ethnicity, and socioeconomic status discrepancies concerning life expectancy, and access to insurance. This program will highlight how racial/ethnic disparities in PAH impact delayed diagnosis, treatment, and other health outcomes. To avoid irreversible damage and select the best treatment plan based on the individual patient profile, regular risk assessment and application of the guidelines are necessary. This activity will present guideline-based recommendations on the diagnosis and treatment of PAH as well as well as a patient case study.


Martha Kingman, DNP, APRN, FNP-C
Family Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, Texas


Release date: August 31, 2022
Expiration date: August 31, 2023
Estimated time to complete activity: 60 minutes



This educational initiative is designed for nurse practitioners, advance practice nurses, physicians, and physician assistants who work in primary care and manage patients with or at risk for PAH.


Upon completion of this educational activity, participants should be able to:

  • Outline the latest PAH guidelines regarding early diagnosis and initiation of therapy, while taking into consideration how racial and ethnic disparities may play into treatment delays and patient outcomes
  • Describe a guideline-directed, evidence-based management plan for PAH that includes consideration of current guidelines, combination therapies, escalation strategies and current clinical trial data and patient-characteristics
  • Discuss how to incorporate patient-focused management tactics to address racial and ethnic disparities and the practical considerations of patients with PAH

There are no fees for participating and receiving CME credit for this activity. During the period of August 31, 2022 through August 31, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.1 hour of pharmacology).

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Physician Continuing Education


Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about AANP or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.


Integrity Continuing Education, Inc. and Global Education Group, requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Martha Kingman, FNP-C, DNP
Advisor: United Therapeutics
Consultant: Aerovate
Consultant/Advisor: Acceleron/Merck, Bayer, Gossamer Bio, Johnson & Johnson/Janssen, Liquidia,

The following project managers/planners: Olivia Benevento, Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Liddy Knight, Rhys Williams, RN, MSN, FNP, Kristin Delisi, NP, Michelle Rizzo, ELS, and Patima Tanapat, PhD reported that they have no financial relationships or relationships to products or devices with ineligible companies related to the content of this CE activity.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest